← All trials
NCT04131582
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2019
- Primary completion
- Dec 15, 2020
- Completion date
- Dec 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 34
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidad de GuanajuatoLead sponsor
- Universidad de GuanajuatoOverall official - principal investigator
- Universidad de GuanajuatoReponsible party - principal investigator
- Hospital Regional Alta Especialidad BajioCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.